| Recruiting | A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer NCT07428044 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Not Yet Recruiting | Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non- NCT06848426 | Jiangxi Provincial People's Hopital | N/A |
| Not Yet Recruiting | Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC NCT06436144 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer NCT06394427 | West China Hospital | — |
| Recruiting | Alectinib Pharmacokinetic in Patients With NSCLC NCT05713006 | Instituto Nacional de Cancerologia de Mexico | Phase 1 / Phase 2 |
| Terminated | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer NCT04432207 | Imugene Limited | Phase 1 |
| Unknown | Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC) NCT03532698 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | — |
| Withdrawn | Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer NCT03628144 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resecta NCT04699721 | Xiangya Hospital of Central South University | Phase 2 |
| Active Not Recruiting | Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC NCT03611738 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Unknown | Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung C NCT03396185 | Betta Pharmaceuticals Co., Ltd. | Phase 2 |
| Completed | A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer NCT03472053 | BioMarck Pharmaceuticals, Ltd. | Phase 2 |
| Terminated | Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy NCT03302247 | Fox Chase Cancer Center | Phase 2 |
| Completed | Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC NCT03543683 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Terminated | Survival Prolongation by Rationale Innovative Genomics NCT03386929 | Worldwide Innovative Network Association | Phase 1 / Phase 2 |
| Completed | Immunotherapy by Nivolumab for HIV+ Patients NCT03304093 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Completed | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 NCT03307785 | Tesaro, Inc. | Phase 1 |
| Unknown | Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients NCT03288870 | Biocad | Phase 2 / Phase 3 |
| Unknown | Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients NCT03334071 | University Hospital Southampton NHS Foundation Trust | N/A |
| Completed | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous No NCT01999673 | Peregrine Pharmaceuticals | Phase 3 |
| Unknown | PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy NCT02035683 | National Cancer Institute, Naples | N/A |
| Terminated | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced N NCT01798485 | Synta Pharmaceuticals Corp. | Phase 3 |
| Completed | Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial NCT02176369 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Unknown | MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous L NCT01656551 | National Cancer Institute, Naples | Phase 3 |
| Completed | A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell NCT01473563 | Eli Lilly and Company | Phase 2 |
| Unknown | Chemotherapy Combined With Whole-body Hyperthermia to Treat Stage IIIB/IV Non Small Cell Lung Cancer NCT01493011 | Xijing Hospital | N/A |
| Terminated | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer NCT01348126 | Synta Pharmaceuticals Corp. | Phase 2 / Phase 3 |
| Unknown | MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer NCT01405586 | National Cancer Institute, Naples | Phase 3 |
| Terminated | Phase II Avastin Trial for Stage IIIB/IV NSCLC NCT00766246 | Pharmatech | Phase 2 |